Press release
Geron Reports Ten Imetelstat Presentations at American Society of Hematology Annual Meeting
Data and analyses highlight the differentiating clinical benefits of imetelstat treatment observed in both the Phase 2 IMerge and IMbark trials Additional
About this update from Geron Corporation
[{"type":"text","content":"\n\nData and analyses highlight the differentiating clinical benefits of imetelstat treatment observed in both the Phase 2 IMerge and IMbark trials\n\n\nAdditional clinical analyses and data presented on the depletion of abnormal clones and disease mutations strongly suggest that imetelstat has disease-modifying activity\n\n\nBiomarker data on reductions in telomerase activity and hTERT expression correlated with clinical outcomes provides evidence of on-target activity of imetelstat\n\n\nAll ten abstracts submitted were accepted for presentation\n\n\nPresentations provide further support of ongoing and upcoming Phase 3 clinical trials of imetelstat\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting. The presentations are available at www.geron.com/r-d/publications.\n\n“Our imetelstat presentations at this year’s ASH provide strong support for our two registration-enabling Phase 3 clinical trials: IMerge, in lower risk MDS and IMpactMF, in refractory MF,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer. “We believe the analyses and data from our Phase 2 IMerge and IMbark trials provide strong evidence of imetelstat’s disease-modifying activity, as well as clinical benefits of durable transfusion independence in MDS and improvement in overall survival in MF.”\n\nLower Risk Myelodysplastic Syndromes (MDS) – Oral Presentation\n\nTitle: Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) (Abstract #658)\n\nThe oral presentation reported long-term efficacy, safety and biomarker data from 38 patients in the IMerge Phase 2 clinical trial, based on a February 4, 2020 cut-off date and a median follow-up of 24 months. Consistent with prior presentations, 42% of patients achieved >8-week red blood cell transfusion independence (RBC-TI) with a median duration of 20 months, which is the longest so far reported with any agent in relapsed/refra...